Advanced in Dehydration

Liang M. Huang

35 Qinghua East Road, 
Beijing, CN 
Clinical Trials:Currently Recruiting for 2 Trials
Advanced in Dehydration
35 Qinghua East Road, 
Beijing, CN 
OverviewLocationsClinical Research

Overview

Liang Huang practices in Beijing, China. Mr. Huang is rated as an Advanced expert by MediFind in the treatment of Dehydration. His top areas of expertise are B-Cell Lymphoma, Non-Hodgkin Lymphoma, Leukemia, Mastectomy, and Bone Marrow Transplant.

His clinical research consists of co-authoring 340 peer reviewed articles and participating in 3 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 4 articles in the study of Dehydration.

Gender
Male

Locations

35 Qinghua East Road, Beijing, 100083, China
Other Locations
1095 Jiefang Avenue, Wuhan, China
35 Qinghua East Road, Haidian, 100083, China
No. 1095 Jiefang Avenue, Wuhan, 430030, China
Union Hospital, Wuhan, 430022, China
399 Ling Ling Road, Shanghai, 200032, China

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

To Observe the Long-term Efficacy and Safety of Dual-target Chimeric Antigen Receptor T Cells in the Treatment of Refractory Relapsed B Cell Hematologic Tumors
To Observe the Long-term Efficacy and Safety of Dual-target Chimeric Antigen Receptor T Cells in the Treatment of Refractory Relapsed B Cell Hematologic Tumors
Enrollment Status: Recruiting
Publish Date: June 18, 2025
Intervention Type: Biological
Study Phase: Phase 1
A Phase II Clinical Study of Anti-CD19 CAR-T Therapy (pCAR-19B) in the Treatment of CD19-positive Relapsed/Refractory B-ALL
A Phase II Clinical Study of Anti-CD19 CAR-T Therapy (pCAR-19B) in the Treatment of CD19-positive Relapsed/Refractory B-ALL
Enrollment Status: Recruiting
Publish Date: July 31, 2024
Intervention Type: Biological
Study Phase: Phase 2
A Phase I Clinical Study of Anti-CD19 CAR-T Therapy (pCAR-19B) in the Treatment of CD19-positive Relapsed/Refractory B-ALL
A Phase I Clinical Study of Anti-CD19 CAR-T Therapy (pCAR-19B) in the Treatment of CD19-positive Relapsed/Refractory B-ALL
Enrollment Status: Completed
Publish Date: March 18, 2022
Intervention Type: Biological
Study Drug: pCAR-19B cells
Study Phase: Phase 1
View 1 Less Clinical Trial

340 Total Publications

CD5 ablation enhances persistence and antitumor potency of engineered T cells by mitigating exhaustion and promoting cytotoxicity.
CD5 ablation enhances persistence and antitumor potency of engineered T cells by mitigating exhaustion and promoting cytotoxicity.
Journal: Journal for immunotherapy of cancer
Published: November 04, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Huang's expertise for a condition
ConditionClose
      View All 7 Advanced Conditions
      View All 42 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile